- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02292550
Study of Safety and Efficacy of LEE011 and Ceritinib in Patients With ALK-positive Non-small Cell Lung Cancer.
A Phase Ib/II Study of the ALK Inhibitor Ceritinib in Combination With the CDK4/6 Inhibitor LEE011 in Patients With ALK-positive Non-Small Cell Lung Cancer
This was a Phase Ib/II study of the ALK inhibitor ceritinib in combination with the CDK4/6 inhibitor LEE011 in patients with ALK-positive non-small cell lung cancer.
The purpose of the study was to determine the MTD/RP2D of the LEE011 and ceritinib combination and evaluate whether the combination was safe and had beneficial effects in ALK-positive advanced non-small cell lung cancer patients.
This trial did not progress to Phase II. Trial population terminated before reaching Phase II
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Marseille cedex 05, France, 13385
- Novartis Investigative Site
-
-
-
-
BO
-
Bologna, BO, Italy, 40138
- Novartis Investigative Site
-
-
MI
-
Rozzano, MI, Italy, 20089
- Novartis Investigative Site
-
-
-
-
Seocho Gu
-
Seoul, Seocho Gu, Korea, Republic of, 06591
- Novartis Investigative Site
-
-
-
-
Catalunya
-
Barcelona, Catalunya, Spain, 08035
- Novartis Investigative Site
-
-
-
-
-
Taipei, Taiwan, 10002
- Novartis Investigative Site
-
-
Taiwan ROC
-
Tainan, Taiwan ROC, Taiwan, 70403
- Novartis Investigative Site
-
-
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Novartis Investigative Site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients must be diagnosed with ALK-positive advanced NSCLC. The tumor must be ALK-positive as determined by ALK rearrangement in ≥15% of cells (as measured by FISH using the Vysis break-apart ALK probe) or by using the Ventana ALK IHC test. The analysis may be performed locally.
- Eastern cooperative oncology group (ECOG) performance status ≤ 2.
- Measurable disease as per RECIST v1.1
- Availability of tumor sample:
For ALK inhibitor naïve patients:
o A representative tumor sample must be submitted. An archival tumor specimen is acceptable
For patients after progression on an ALK inhibitor:
o A new tumor biopsy is required unless a biopsy performed after progression on the patient's most recent ALK inhibitor is available for submission For all patients a newly obtained tumor specimen must be submitted if no appropriate archival sample is available. In the event that no sample is available and a new biopsy cannot be obtained, enrollment may be considered after discussion with the sponsor.
Exclusion Criteria:
For Phase I part:
o Patients who have not previously received at least one line of therapy for ALK-positive NSCLC
For Phase II part:
- Group A: prior therapy with any ALK inhibitor is not permitted.
- Group B: progression following any ALK inhibitor(s) other than ceritinib is required and the last dose of the ALK inhibitor must be no more than 60 days prior to the first dose of study drug. Prior ceritinib is not permitted.
- Group C: progression following ceritinib is required and the last dose of ceritinib must be no more than 60 days prior to the first dose of study drug.
- Patients who have previously been unable to tolerate ceritinib, in the opinion of the investigator. Exceptions to this exclusion include nausea, vomiting and diarrhea in patients taking ceritinib under fasted conditions.
- Patients with symptomatic central nervous system (CNS) metastases who are neurologically unstable or require increasing doses of steroids or local CNS-directed therapy to control their CNS disease
- Patients with abnormal laboratory values during screening and on day 1 of pre-dose
- Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of ceritinib or LEE011
- Patients who are currently receiving treatment (that cannot be discontinued at least 1 week prior to the initiation of the study) with agents that are known to be any of the following: strong inducers or inhibitors of CYP3A4/5; sensitive substrates of CYP3A; substrates of CYP3A4/5 or CYP2C9 with a narrow therapeutic index.
- Patient has a history of pancreatitis or history of increased amylase or lipase that was due to pancreatic disease.
- Patient with impaired cardiac function or any clinically significant uncontrolled cardiac disease, and/or, cardiac repolarization abnormality, including any of the following:
Clinically significant heart disease such as CHF requiring treatment (NYH grade ≥ 2), history of angina pectoris, myocardial infarction, symptomatic pericarditis, or coronary artery bypass graft (CABG) within 6 months prior to study entry, documented cardiomyopathy, or left ventricular ejection fraction (LVEF) < 50% as determined by multiple gated acquisition scan (MUGA) or echocardiogram (ECHO).
Uncontrolled systolic blood pressure (SBP) ≥160 mmHg and/or diastolic blood pressure (DBP) ≥100 mmHg, with or without anti-hypertensive medication. Initiation or adjustment of antihypertensive medication (s) is allowed prior to screening, Systolic blood pressure (SBP) <90 mmHg Standard 12-lead ECG values defined as the mean of the triplicate ECGs and assessed by central laboratory
- QTcF interval at screening >450 msec (using Fridericia's correction)
- Resting heart rate <50 bpm or > 90 bpm
Long QT syndrome or family history of idiopathic sudden death or congenital long QT syndrome, or any of the following:
- Risk factors for Torsades de Pointe (TdP) including uncorrected hypokalemia or hypomagnesemia, history of cardiac failure, or history of clinically significant/symptomatic bradycardia
- Concomitant medication(s) with a known risk to prolong the QT interval and/or known to cause Torsades de Pointe that cannot be discontinued or replaced by safe alternative medication (e.g. within 5 half-lives or 7 days prior to starting study drug)
- Inability to determine the QTcF interval Clinically significant cardiac arrhythmias (e.g., ventricular tachycardia), complete left bundle branch block, high-grade AV block (e.g., bifascicular block, Mobitz type II and third degree AV block).
Other protocol-defined inclusion/exclusion criteria may apply.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Ribociclib 100 mg + Ceritinib 300 mg
LEE011 capsule for oral use (ribociclib) and Ceritinib for oral use
|
CDK 4/6 inhibitor
Other Names:
ALK inhibitor
Other Names:
|
Experimental: Ribociclib 100 mg + Ceritinib 450 mg
LEE011 capsule for oral use (ribociclib) and Ceritinib for oral use
|
CDK 4/6 inhibitor
Other Names:
ALK inhibitor
Other Names:
|
Experimental: Ribociclib 200 mg + Ceritinib 300 mg
LEE011 capsule for oral use (ribociclib) and Ceritinib for oral use
|
CDK 4/6 inhibitor
Other Names:
ALK inhibitor
Other Names:
|
Experimental: Ribociclib 200 mg + Ceritinib 450 mg
LEE011 capsule for oral use (ribociclib) and Ceritinib for oral use
|
CDK 4/6 inhibitor
Other Names:
ALK inhibitor
Other Names:
|
Experimental: Ribociclib 300 mg + Ceritinib 450 mg
LEE011 capsule for oral use (ribociclib) and Ceritinib for oral use
|
CDK 4/6 inhibitor
Other Names:
ALK inhibitor
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence rate of dose limiting toxicities (DLTs) during the first cycle of treatment (Phase Ib )
Time Frame: 1 month
|
Maximum Tolerated Dose(s) (MTD(s)) and/or recommended phase 2 dose (RP2D(s)) and schedule of LEE011 in combination with ceritinib in ALK-positive non-small cell lung cancer (NSCLC) patients. Cycle = 28 days |
1 month
|
Overall Response Rate (ORR) as per RECIST v1.1
Time Frame: Up to 24 months
|
Preliminary anti-tumor activity of the LEE011 and ceritinib combination
|
Up to 24 months
|
Exposure to LEE011 and ceritinib (Phase Ib )
Time Frame: Up to 6 months
|
Measurement of pharmacokinetics (PK) parameters (AUC0-24h at C1D15)
|
Up to 6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall Response Rate (ORR) - Phase Ib & II
Time Frame: Up to 24 months
|
Preliminary measure of anti-tumor activity of LEE011 and ceritinib combination
|
Up to 24 months
|
Frequency of adverse events/serious adverse events
Time Frame: Up to 24 months
|
Characterization of the safety and tolerability of the LEE011 and ceritinib combination as determined by changes in laboratory values and electrocardiograms
|
Up to 24 months
|
PK parameters of LEE011 and ceritinib
Time Frame: Up to 6 months
|
Characterization of the PK of LEE011 and ceritinib
|
Up to 6 months
|
Frequency of dose interruptions and dose reductions (phase lb & ll)
Time Frame: Up to 24 months
|
Characterization of tolerability
|
Up to 24 months
|
Progression free survival (PFS) per RECIST v1.1 - Phase Ib & II
Time Frame: Up to 24 months
|
Preliminary measures of anti-tumor activity of LEE011 and ceritinib combination
|
Up to 24 months
|
Duration of response (DOR)
Time Frame: Up to 24 months
|
Preliminary measure of anti-tumor activity of LEE011 and ceritinib combination
|
Up to 24 months
|
Time to response (TTR) - Phase Ib & II
Time Frame: Up to 24 months
|
Preliminary measures of anti-tumor activity of LEE011 and ceritinib combination
|
Up to 24 months
|
Disease Control Rate (DCR) - Phase Ib & II
Time Frame: Up to 24 months
|
Preliminary measures of anti-tumor activity of LEE011 and ceritinib combination
|
Up to 24 months
|
Overall survival (OS) - Phase Ib & II
Time Frame: Up to 24 months
|
Preliminary measures of anti-tumor activity of LEE011 and ceritinib combination
|
Up to 24 months
|
Severity of adverse events/serious adverse events
Time Frame: Up to 24 months
|
Characterization of the safety and tolerability of the LEE011 and ceritinib combination as determined by changes in laboratory values and electrocardiograms.
|
Up to 24 months
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Neoplasms
- Lung Diseases
- Neoplasms by Site
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Carcinoma, Bronchogenic
- Bronchial Neoplasms
- Lung Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Protein Kinase Inhibitors
- Ceritinib
Other Study ID Numbers
- CLEE011X2110C
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Non-small Cell Lung Cancer
-
WindMIL TherapeuticsBristol-Myers SquibbTerminatedNSCLC | Lung Cancer | Lung Cancer Metastatic | Lung Cancer, Non-small Cell | Non Small Cell Lung Cancer | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Non Small Cell Lung Cancer MetastaticUnited States
-
University of California, San FranciscoAstraZenecaActive, not recruitingStage IIIA Non-Small Cell Lung Cancer | Stage I Non-Small Cell Lung Cancer | Stage IA Non-Small Cell Lung Cancer | Stage IB Non-Small Cell Lung Cancer | Stage II Non-Small Cell Lung Cancer | Stage IIA Non-Small Cell Lung Cancer | Stage IIB Non-Small Cell Lung CancerUnited States
-
University of Wisconsin, MadisonNational Cancer Institute (NCI)CompletedStage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Extensive Stage Small Cell Lung Cancer | Recurrent Small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer | Healthy, no Evidence of Disease | Limited Stage Small Cell Lung... and other conditionsUnited States
-
AIO-Studien-gGmbHBristol-Myers Squibb; Eli Lilly and Company; Merck Sharp & Dohme LLC; Pfizer; Gilead... and other collaboratorsRecruitingSmall-cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Non-small Cell Lung Cancer Stage I | Metastatic Non-small Cell Lung Cancer (NSCLC) | Non Small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer Stage IIGermany
-
Alexander ChiNot yet recruitingNon-small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Stage I | Non-small Cell Carcinoma | Non-small Cell Lung Cancer Stage IIChina
-
National Cancer Institute (NCI)TerminatedStage IIIA Non-small Cell Lung Cancer | Stage IA Non-small Cell Lung Cancer | Stage IB Non-small Cell Lung Cancer | Stage IIA Non-small Cell Lung Cancer | Stage IIB Non-small Cell Lung CancerUnited States
-
National Cancer Institute (NCI)Not yet recruitingStage IIIA Non-small Cell Lung Cancer | Stage IA Non-small Cell Lung Cancer | Stage IB Non-small Cell Lung Cancer | Stage IIA Non-small Cell Lung Cancer | Stage IIB Non-small Cell Lung CancerCanada
-
Karen KellyBristol-Myers Squibb; National Cancer Institute (NCI); TransgeneCompletedStage IIIA Non-Small Cell Lung Cancer | Stage IIIB Non-Small Cell Lung Cancer | Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer | Stage I Non-Small Cell Lung Cancer | Stage II Non-Small Cell Lung CancerUnited States
-
Memorial Sloan Kettering Cancer CenterAstraZenecaRecruitingNSCLC | Lung Cancer | Non-small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Stage I | PD-L1 Gene Mutation | Non-small Cell Lung Cancer Stage IIIA | Non-small Cell Lung Cancer Stage IIUnited States
-
Virginia Commonwealth UniversityNational Cancer Institute (NCI)WithdrawnStage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IIA Non-small Cell Lung Cancer | Stage IIB Non-small Cell Lung CancerUnited States
Clinical Trials on Ribociclib
-
Institut fuer FrauengesundheitNovartis Pharmaceuticals; AGO Breast Study Group e.V.RecruitingBreast Cancer | Breast Neoplasms | Advanced Breast Cancer | Breast Neoplasm Female | Breast Cancer Female | HER2-negative Breast Cancer | Hormone Receptor-positive Breast CancerGermany
-
Fox Chase Cancer CenterTerminatedSquamous Cell Carcinoma of the Head and NeckUnited States
-
Novartis PharmaceuticalsRecruiting
-
Novartis PharmaceuticalsCompletedNormal Hepatic Function | Impaired Hepatic FunctionUnited States
-
Hadassah Medical OrganizationUnknownSoft Tissue Sarcoma | LiposarcomaIsrael
-
Novartis PharmaceuticalsNot yet recruiting
-
Nader SanaiNovartis; Barrow Neurological Institute; Ivy Brain Tumor CenterActive, not recruitingGlioblastoma Multiforme | MeningiomaUnited States
-
Assaf-Harofeh Medical CenterUnknownSoft-Tissue Sarcoma | Liposarcomas, Dedifferentiated | Liposarcoma - Well Differentiated | Liposarcoma; Mixed TypeIsrael
-
Children's Hospital Medical Center, CincinnatiNovartisTerminatedHigh Grade Glioma | Diffuse Intrinsic Pontine Glioma | Bithalamic High Grade GliomaUnited States